



# Vitiligo

Vitiligo is a chronic skin condition characterized by the progressive loss of pigmentation, resulting in irregular white patches on the skin. This condition occurs when melanocytes, the cells responsible for producing pigment (melanin), are destroyed or stop functioning. While vitiligo can affect individuals of any age, gender, or ethnicity, its appearance is more pronounced in individuals with darker skin tones. It is estimated that approximately 1% of the global population is affected by vitiligo, with about one-third of patients having a family history of the disorder.

### **Pathophysiology and Etiology**

The exact cause of vitiligo remains unclear, although it is widely believed to be an autoimmune disorder. In vitiligo, the body's immune system mistakenly targets and destroys melanocytes in the skin, mucous membranes, eyes, and hair follicles. This leads to the formation of depigmented patches, which can vary in size and location. Vitiligo often begins in areas of skin that are more susceptible to damage, such as the hands, feet, and face. Trauma or sunburn can also trigger the onset or exacerbation of lesions in susceptible individuals.


Vitiligo has a strong genetic component, with a hereditary predisposition observed in about 30% of cases. Certain genetic factors, particularly those involved in immune regulation, are thought to contribute to the development of the condition. Additionally, vitiligo is frequently associated with other autoimmune disorders such as alopecia areata, autoimmune thyroid diseases, Addison's disease, pernicious anemia, and type 1 diabetes.

#### **Clinical Features**

Vitiligo is typically characterized by the appearance of well-defined, depigmented patches of skin. The lesions are often asymptomatic, although some patients may experience mild pruritus or stinging sensations. The affected areas are usually devoid of pigment, but the skin may retain a characteristic "halo" effect, particularly in early stages. Vitiligo lesions can occur on any part of the body, including the face, hands, feet, and genital areas.

The condition is classified into several subtypes, each with distinct characteristics:

- > *Vitiligo vulgaris:* The most common form, characterized by symmetric depigmented patches on both sides of the body.
- > **Segmental vitiligo**: A form that presents as a localized, unilateral distribution of lesions, typically along a dermatome.





- > *Trichrome vitiligo*: A variant in which a patch of depigmented skin is surrounded by areas of hypopigmentation (lighter than normal skin tone).
- > *Inflammatory vitiligo*: Characterized by a more rapid onset with erythema and inflammation around the depigmented areas.

# **Diagnosis**

The diagnosis of vitiligo is primarily clinical and is based on the patient's medical history, clinical presentation, and the characteristic appearance of the lesions. In cases where the diagnosis is uncertain, or if there is a need to rule out other conditions, additional diagnostic tools may be employed:

- > Wood's lamp examination: A special ultraviolet light used to detect areas of hypopigmentation more clearly.
- > *Skin biopsy:* Occasionally performed to assess the degree of melanocyte destruction or to differentiate vitiligo from other dermatologic conditions.
- > **Blood tests**: To evaluate for associated autoimmune diseases, such as thyroid dysfunction, and to assess the patient's overall immune status.

## **Treatment Options**


Currently, no cure exists for vitiligo, but several treatment strategies can help manage symptoms and promote repigmentation of the affected skin. Treatment options vary depending on the extent, location, and severity of the vitiligo lesions, as well as patient preferences.

# **Topical Treatments**

- > **Topical Corticosteroids**: These are the first-line treatment for localized vitiligo, as they can reduce inflammation and help to stabilize the immune response. However, prolonged use can lead to skin thinning and other side effects.
- > Topical Ruxolitinib Cream (Opzelura): Recently FDA-approved, this Janus kinase (JAK) inhibitor is applied twice daily and has been shown to improve repigmentation in patients with mild to moderate vitiligo, especially those with facial involvement.
- > Topical Calcineurin Inhibitors (e.g., Pimecrolimus, Tacrolimus): Non-steroidal alternatives to corticosteroids, useful in areas sensitive to steroid side effects, such as the face and genital areas.

## **Phototherapy**

➤ *Narrow-band Ultraviolet B (nbUVB):* This is one of the most effective treatments for widespread vitiligo. It involves exposing the skin to controlled UVB light 2-3 times per week. Although slow to show results, this treatment can lead to significant repigmentation, especially in individuals with early-stage vitiligo.





> Excimer Laser: This targeted form of UVB therapy is used for localized lesions, especially on the face and hands. It can deliver higher doses of UVB to small areas, promoting repigmentation in cases where conventional phototherapy may be ineffective.

#### **Surgical Treatments**

For patients with stable vitiligo who do not respond to medical treatments, **autologous melanocyte transplantation** may be considered. This technique involves transplanting healthy melanocytes from the patient's own skin into depigmented areas. This procedure is particularly effective for small, stable patches but may result in scarring or a cobblestone appearance of the grafted skin.

### **Depigmentation Therapy**

For patients with extensive vitiligo, depigmentation therapy can be considered. This involves the use of chemicals (such as monobenzone) to bleach the remaining pigmented skin, creating a uniform appearance. However, this therapy is irreversible and can have significant cosmetic and psychological effects.

#### **Cosmetic Options**


For patients who do not respond to medical or surgical treatments, cosmetic camouflage can be used to mask the appearance of vitiligo. Products such as dermablend, Covermark, and Zanderm can effectively conceal depigmented areas, helping individuals manage the cosmetic aspects of the disease. Sunless tanning products may also be used to darken the skin around vitiligo patches, making the differences in skin tone less noticeable.

#### **Preventive Measures and Sun Protection**

Because vitiligo involves areas of skin that lack pigmentation, these regions are more vulnerable to sunburn and damage. Sun protection is critical for all individuals with vitiligo. Recommendations include daily application of broad-spectrum UVA/UVB sunscreen, wearing protective clothing, and avoiding prolonged sun exposure.

#### Conclusion

Vitiligo is a complex autoimmune condition with significant cosmetic and psychological impacts on affected individuals. Although the pathophysiology remains incompletely understood, advances in treatment, particularly with the introduction of JAK inhibitors and phototherapy options, offer hope for improved outcomes. Continued research into the underlying mechanisms of vitiligo and the development of novel therapies is essential for providing more effective management options and ultimately finding a cure.





#### References

- Huggins, R. H., & Norris, D. A. (2016). Vitiligo: Pathogenesis, clinical presentation, and treatment options. Journal of Clinical and Aesthetic Dermatology, 9(11), 12-19.
- ❖ Kemp, E. H., & Ziegler, S. R. (2019). Topical treatments for vitiligo: A review of current therapies and future directions. *Dermatologic Therapy*, 32(3), e12702. <a href="https://doi.org/10.1111/dth.12702">https://doi.org/10.1111/dth.12702</a>
- Krueger, G. G., Lim, H. W., & Naunton, A. (2020). Phototherapy for vitiligo: An overview. *Journal of Dermatological Treatment*, 31(4), 305-313. <a href="https://doi.org/10.1080/09546634.2019.1681492">https://doi.org/10.1080/09546634.2019.1681492</a>
- ◆ Patel, P., & Gupta, A. (2020). Vitiligo: Pathogenesis and treatment. *Indian Journal of Dermatology*, 65(1), 45-55. <a href="https://doi.org/10.4103/ijd.ijd\_98\_19">https://doi.org/10.4103/ijd.ijd\_98\_19</a>
- Rashid, R. M., & McCormick, T. S. (2014). Vitiligo: Epidemiology, pathogenesis, and treatment. *Dermatologic Clinics*, 32(2), 209-218. https://doi.org/10.1016/j.det.2014.01.004
- **❖** Zand, V., et al. (2022). Efficacy of topical ruxolitinib in the treatment of vitiligo: A randomized controlled trial. *JAMA Dermatology*, 158(3), 354-361. <a href="https://doi.org/10.1001/jamadermatol.2021.4637">https://doi.org/10.1001/jamadermatol.2021.4637</a>